Liminatus Pharma, Inc. (LIMN) income statement
LIMNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as LIMNW
$2.51−0.30 (-10.68%)
Close on Nov 20, 2026Market cap $168.57MP/E –Yield –
Liminatus Pharma, Inc. financial ratios
See a number that looks wrong?